Skip to Content

Pro Medicus Ltd - Stock Quote PMCUF

Rating as of

Morningstar's Pro Medicus Ltd Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics - PMCUF

Pro Medicus Ltd's Company Profile

Business Description

Pro Medicus is a healthcare IT company specialising in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are U.S. private academic hospitals. In fiscal 2021, Pro Medicus earned 74% of revenue in North America, 20% from Australia and the remaining 6% in Europe.

Contact
450 Swan Street, Richmond
Melbourne, VIC, 3121, Australia
T +61 394298800
Industry Health Information Services
Most Recent Earnings
Fiscal Year End Jun 30, 2022
Stock Type
Employees 75